Company Profile
Valeant Pharmaceuticals International
Company Overview
Valeant Pharmaceuticals International (NYSE: VRX) is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant has made rapid strides since a new management team was appointed four years ago with a strategic vision and renewed focus on its specialty pharmaceuticals business. The company has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
In 2006, Valeant total revenues were $907 million, including product sales of $826 million that were generated through 370 products and more than 2,200 SKUs. Based in Aliso Viejo, California, Valeant employs 3,500 people globally.
Company History
www.Kinerase.com
Welcome to younger looking skin without needles or surgery. Kinerase® is a gentle,
yet effective skin care regimen scientifically shown to improve the appearance
of skin aging, sun damage, blotchiness and roughness.
The power behind Kinerase is kinetin* — a plant-based extract that helps
visibly improve the appearance of aging and sun-damaged skin. Kinetin
is the substance that actually prevents plant leaves from drying out
and withering. Kinerase formulations deliver the remarkable
restorative powers of kinetin directly to the skin— improving
skin's ability to retain moisture.
The latest innovation from Kinerase is Pro+Therapy. Designed to
work with the core products, Pro+Therapy is available exclusively
through physicians and kinerase.com. The Pro+Therapy difference
is zeatin† — a next generation plant-based extract derived from
plant RNA that is proprietary to Valeant. The advanced treatment
options of Pro+Therapy are designed to help break topical cosmetic
plateaus and take results to the next level.
Kinerase's complete regimen of products works synergistically to reveal
more radiant, visibly tighter skin.
Notable Products / Brands
Kinerase, Effudex, Dermatix, Retigabine
Notable Accomplishments / Recognition
Valeant Pharmaceuticals International (NYSE: VRX) is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant has made rapid strides since a new management team was appointed four years ago with a strategic vision and renewed focus on its specialty pharmaceuticals business. The company has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
In 2006, Valeant total revenues were $907 million, including product sales of $826 million that were generated through 370 products and more than 2,200 SKUs. Based in Aliso Viejo, California, Valeant employs 3,500 people globally.